Hypercoagulability in Ovarian Cancer Revisited: A Prospective Analysis of Coagulation and Platelet Activation Markers

Autor:	John L. Francis, Alane Drexler, Patricia Faust, Liza Robles, Mildred Amaya, Ali Amirkhosravi, Florian Länger, Edward Reyes, Glenn Bigsby, Hina Desai, Enriqueta Coll
Rok vydání:	2006
Předmět:	medicine.medical_specialty Pathology business.industry Immunology Cell Biology Hematology medicine.disease Thrombophilia Biochemistry Gastroenterology Metastasis Whole Blood Coagulation Time Internal medicine medicine Thromboplastin Platelet Platelet activation Ovarian cancer business Whole blood
Zdroj:	Blood. 108:1762-1762
ISSN:	1528-0020 0006-4971
DOI:	10.1182/blood.v108.11.1762.1762
Popis:	Coagulation and platelet activation occurs in patients with ovarian cancer, and several factors underlying such hypercoagulability have been implicated in tumor growth and metastasis. The incidence of venous thromboembolism throughout the course of ovarian cancer is high, and identification of hypercoagulable patients may be important not only for effective thromboprophylaxis, but also for future anti-hemostatic treatment strategies targeting disease progression. The purpose of this prospective study was therefore, first, to characterize in more detail, the hypercoagulable state in patients with ovarian tumors and, second, to define markers of coagulation or platelet activation that specifically identify patients with malignant disease. Thirty nine patients presenting to our institution with an ovarian mass of unknown type (41–69 yrs) and 32 age-matched controls were included in the study. Pre- and postoperative (7–14 days) blood samples were collected, and all whole blood (WB) analyses were performed and plasmas prepared and frozen within 2 hours thereafter. WB thrombelastography (TEG) served for global coagulation assessment. D-Dimer and prothrombin fragment F1+2 were used as markers of coagulation activation. Soluble CD40 ligand (sCD40L), soluble P-selectin, platelet-monocyte conjugates, and platelet-derived microparticles (PMP) were measured to assess in vivo platelet activation. Tissue factor (TF) antigen and TF+ microparticles were quantified in plasma by ELISA and flow cytometry, respectively. Compared to controls, mean values for TEG-R, a measure of clotting time, and TEG-MA, a measure of clot strength, were significantly decreased (10.1 vs. 7.3 min, P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b4d39d2b0e447cdf53671dccc20857d9 https://doi.org/10.1182/blood.v108.11.1762.1762 Zobrazit plný text záznamu